FDA advisors vote no to Capricor's DMD therapy
FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
Newsletters and Deep Dive digital magazine
FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.
J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.
After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.
Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.
Editor's Picks
Newsletters and Deep Dive
digital magazine